In a phase I/II clinical trial, derazantinib exhibited encouraging anti-tumor efficacy and tolerable safety profiles among patients diagnosed with advanced, unresectable ICC harboring FGFR2 fusion, resulting in a notable response rate of 20.7% and a disease control rate of 82.8% [186]. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.